Advertisement

Drugs & Aging

, Volume 35, Issue 7, pp 657–663 | Cite as

Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials

  • Jennifer K. Burton
  • Richard Papworth
  • Caroline Haig
  • Colin McCowan
  • Ian Ford
  • David J. Stott
  • Terence J. QuinnEmail author
Original Research Article

Abstract

Background

Statins have been associated with later life, long-term care admission in observational studies. However, by preventing vascular events, statins may also prevent or delay admission. We wished to determine statin and long-term care admission associations in a randomised controlled trial context, and describe associations between long-term care admission and other clinical and demographic factors.

Methods

We used extended follow-up of two randomised trial populations, using national data to assign the long-term care admission outcome, and included individuals screened or recruited to two large randomised trials of pravastatin 40 mg daily—the West of Scotland Coronary Prevention Study (WOSCOPS) and the pravastatin in elderly individuals at risk of vascular disease (PROSPER) study. We described univariable and multivariable analyses of potential predictors of long-term care admission with corresponding survival curves of incident long-term care admission and analyses adjusted for competing risk.

Results

In total 11,015 (10%) of the trial participants were admitted to long-term care. There was no difference between participants in the statin or placebo arms of either trial in regard to admissions to long-term care. On multivariable analyses, independent associations with incident long-term care admission in the PROSPER trial were age (hazard ratio [HR] 1.06 per year, 95% confidence interval [CI] 1.03–1.09) and male sex (HR 0.72, 95% CI 0.53–0.99). In the WOSCOPS, age (HR 1.12 per year, 95% CI 1.10–1.13) and increasing social deprivation (HR 1.05, 95% CI 1.03–1.08) were associated with incident long-term care admission.

Conclusion

We did not demonstrate an association between historical statin use and future long-term care admission. The strongest associations with incident long-term care admission were non-modifiable factors of age, sex and socioeconomic deprivation.

Notes

Acknowledgements

All contributors to this analysis are listed as authors.

Author Contributions

JKB drafted the manuscript; RP, CH, CM, IF handled the data management and analyses; and DJS and TJQ created the protocol and awarded funding. All authors contributed to interpretation of data and the final manuscript.

Compliance with Ethical Standards

Funding

This work was supported by the NHS Scotland, Chief Scientist Office (HICG/1/14).

Conflict of interest

Jennifer K. Burton, Richard Papworth, Caroline Haig, Colin McCowan, Ian Ford, and Terence J. Quinn declare that they have no relevant conflicts of interest that may be relevant to this manuscript. David J. Stott received research funding support from Bristol-Myers Squibb for the PROSPER and WOSCOPS studies.

Sponsor’s role

The sponsors played no part in the design, conduct or analysis of this study.

References

  1. 1.
    Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.CrossRefGoogle Scholar
  2. 2.
    Davies JT, Delfino SF, Feinberg CE, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13–29.CrossRefGoogle Scholar
  3. 3.
    McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;(1):CD003160.Google Scholar
  4. 4.
    Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.CrossRefGoogle Scholar
  5. 5.
    Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ. 2000;320:241–6.CrossRefGoogle Scholar
  6. 6.
    Quinn TJ, McArthur K, Ellis G, Stott DJ. Functional assessment in older people. BMJ. 2011;343:d4681.CrossRefGoogle Scholar
  7. 7.
    Rubin EB, Buehler AE, Halpern SD. States worse than death among hospitalized patients with serious illnesses. JAMA Intern Med. 2016;176:1557–9.CrossRefGoogle Scholar
  8. 8.
    Ribbe MW, Ljunggren G, Steel K, et al. Nursing homes in 10 nations: a comparison between countries and settings. Age Ageing. 1997;26(Suppl 2):3–12.CrossRefGoogle Scholar
  9. 9.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.CrossRefGoogle Scholar
  10. 10.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRefGoogle Scholar
  11. 11.
    WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1995;76:485–91.CrossRefGoogle Scholar
  12. 12.
    Ford I, Blauw GJ, Murphy MB, et al. A prospective study of pravastatin in the elderly at risk (PROSPER) screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med. 2002;3:8.CrossRefGoogle Scholar
  13. 13.
    Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–80.CrossRefGoogle Scholar
  14. 14.
    The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45–64 years: trial design. J Clin Epidemiol. 1992;45(8):849–60.CrossRefGoogle Scholar
  15. 15.
    Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 1999;84(10):1192–7.CrossRefGoogle Scholar
  16. 16.
    Carstairs V, Morris R. Deprivation and health in Scotland. Health Bull (Edinb). 1990;48(4):162–75.PubMedGoogle Scholar
  17. 17.
    McLoone P, Boddy FA. Deprivation and mortality in Scotland, 1981 and 1991. BMJ. 1994;309(6967):1465–70.CrossRefGoogle Scholar
  18. 18.
    Barry SJ, Dinnett E, Kean S, et al. Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study. PLoS One. 2013;8(9):e75379.CrossRefGoogle Scholar
  19. 19.
    Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open. 2013;3(3):e002333.CrossRefGoogle Scholar
  20. 20.
    Pruchno R, Hahn S, Wilson-Genderson M. Cigarette smokers, never-smokers, and transitions: implications for successful aging. Int J Aging Hum Dev. 2012;74(3):193–209.CrossRefGoogle Scholar
  21. 21.
    Harrison JK, Walesby KE, Hamilton L, et al. Predicting discharge to institutional long-term care following acute hospitalisation: a systematic review and meta-analysis. Age Ageing. 2017;46(4):547–58.CrossRefGoogle Scholar
  22. 22.
    Luppa M, Luck T, Weyerer S, et al. Prediction of institutionalization in the elderly. A systematic review. Age Ageing. 2010;39(1):31–8.CrossRefGoogle Scholar
  23. 23.
    Doubal FN, Ali M, Batty GD, et al. Big data and data repurposing: using existing data to answer new questions in vascular dementia research. BMC Neurol. 2017;17(1):72.CrossRefGoogle Scholar
  24. 24.
    Ruscica M, Macchi C, Pavanelo C, Corsini A, Sahebkar A, Sirtoni CR. Appropriateness of statin prescription in the ederly. Eur J Intern Med. 2018;50:33–40.CrossRefGoogle Scholar
  25. 25.
    Murphy C, Bennett K, Fahey T, et al. Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open. 2015;5(7):e008017.CrossRefGoogle Scholar
  26. 26.
    Lloyd SM, Stott DJ, de Craen AJ, et al. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One. 2013;8(9):e72642.CrossRefGoogle Scholar
  27. 27.
    Sever PS, Chang CL, Gupta AK, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11 year mortality follow-up of the lipid lowering arm in the UK. Eur Heart J. 2011;32:2525–32.CrossRefGoogle Scholar
  28. 28.
    Ridker PM, Lonn E, Paynter NP, Glynn R, Yusuf S. Primary prevention with statin therapy in the elderly. Circulaton. 2017;135:1979–81.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Alzheimer Scotland Dementia Research Centre and Centre for Cognitive Ageing and Cognitive EpidemiologyUniversity of EdinburghEdinburghUK
  2. 2.Robertson Centre for BiostatisticsUniversity of GlasgowGlasgowUK
  3. 3.Academic Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, Glasgow Royal InfirmaryUniversity of GlasgowGlasgowUK

Personalised recommendations